About Abliva

Company Description

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly.

The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, will enter the clinic in 2022.

Year founded

2000

Served area

Worldwide

Headquarters

Scheeletorget 1, 22381 Lund – Sweden

Shareholder information

Shares outstanding

1,056,299,165

IPO

Jan. 1, 2000

Stock exchange(s)

Nasdaq Stockholm

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.